Indiana State Department of Health
An Equal Opportunity Employer

Mitchell E. Daniels, Jr.
Governor

Gregory N. Larkin, M.D., F.A.A.F.P.
State Health Commissioner

DATE: December 21, 2012

TO: All Local Health Departments
Attn: Chief Food Inspection Officer

FROM: A. Scott Gilliam, MBA, CP-FS
Director, Food Protection Program

ASG

SUBJECT: P&J TRADING Recall

SUGGESTED ACTION: **Unclassified Recall; After being notified by the US FDA that testing found the SLIMDIA REVOLUTION products contain Sibutramine which is an appetite suppressant that was FDA-approved for the treatment of obesity; Recommend notification of affected stores via phone, fax or e-mail.**

From the information provided by FDA, the recalled products were distributed in the State of Indiana. The active drug ingredient is not listed on the label for these products. This product was distributed nationwide in US from March 2012 to December 2012. Detail store information is not available at this time. In addition, if any recalled products are found, please notify this office at 317-351-7190.

****

Recall -- Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

P&J Trading Issues a Voluntary Recall of All Lots of the Dietary Supplements Slimdia Revolution

Contact
Consumer
Seung ("Paul") Bum Kang
1-714-726-6544

FOR IMMEDIATE RELEASE - December 19, 2012 - P&J TRADING announced today that it is conducting a voluntary nationwide recall of the company's dietary supplements sold under the brand name SLIMDIA REVOLUTION specific to the following product below. There is no identifying lot number.

SLIMDIA REVOLUTION (bottles 30 capsules)

P&J TRADING is conducting a voluntary recall after being notified by the US FDA that testing found the SLIMDIA REVOLUTION products, specific to the above lot numbers, contain Sibutramine. Sibutramine is an appetite suppressant that was FDA-approved for the treatment of obesity. It is Schedule IV controlled substance and because of the risks associated with its use, it should be taken only under the direct supervision of qualified health care professional. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Sibutramine has been withdrawn from U.S marketplace. The active drug ingredient is not listed on the label for these products. This product was distributed nationwide in US from March 2012 to December 2012.

P&J TRADING advises any customers in possession of the SLIMDIA REVOLUTION products to return any unused product for a full refund to the company directly. Customers can call 714-726-6544 (9am to 5pm, Monday-Friday) for instructions on the return and refund process.

Any adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's Med Watch Adverse Event Reporting program either online, by regular mail or by fax.

- **Online**: http://www.fda.gov/MedWatch/report.htm [1]
- **Regular Mail**: use postage-paid, pre-addressed Form FDA 3500 available at: http://www.fda.gov/MedWatch/getforms.htm[2]. Mail to address on the pre-addressedform.
- **Fax**: 1800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. P&J TRADING is committed to improving its products and avoiding future recall issues by sourcing higher quality raw ingredients and expanding testing. P&J TRADING promises its customers the highest possible quality and welcomes the recall process as future evidence of our commitment to our brands, products and consumers.

###

RSS Feed for FDA Recalls Information[3] [what's this?[4]]

Photo: Product Labels[5]